Khurem Farooq, Aiolos Bio CEO
Aiolos Bio launches with $245M Series A, chasing one of asthma’s hottest targets
Two Genentech vets have landed one of biotech’s largest Series A rounds of 2023 as they launch Aiolos Bio to advance an asthma drug in …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.